CANF Stock — Can-Fite Biopharma Ltd: Cash, EV, Pipeline

Share price

$2.24

Market cap

$4.8M

Cash

$5.5M

Enterprise value

-$0.7M

Balance sheet

Cash	$5.5M
Debt	$0.0M
Net cash	$5.5M
Enterprise value	-$0.7M
Basic shares	2.2M shares
Fully diluted shares	4.0M shares
Fully diluted market cap	$8.9M
Cash per share	$2.56

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading CANF daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 12 - Nov 23	Piclidenoson	Phase 2	Lowe Syndrome	—
Jan 12 - Feb 23	piclidenoson	Phase 3	Plaque Psoriasis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Piclidenoson

Stage not disclosed · Active Modality: orally bioavailable small molecule

Aliases CF101

Target A3AR (adenosine A3 receptor)

Indications

Plaque Psoriasis (Phase 3)
Lowe Syndrome (Phase 3)

Status note Most advanced molecule per filing, but no current trial or indication stated in excerpts. Failure history (per risk factors): Phase 3 dry-eye missed primary (complete corneal clearing); Phase 2 glaucoma no IOP separation; two Phase 2b RA studies missed primaries; Phase 3 ACROBAT (RA) ended on IDMC interim recommendation; Phase 2/3 psoriasis missed primary (further analysis suggests potential in moderate-severe psoriasis). No explicit discontinuation.

Namodenoson

Stage not disclosed · Active Modality: orally bioavailable small molecule

Aliases CF102

Target A3AR (adenosine A3 receptor)

Indications

Hepatocellular Carcinoma (Phase 3)
Cirrhosis (Phase 3)
Pancreatic Adenocarcinoma (Phase 3)

Status note Among the two most advanced molecules; no current trial or indication stated in excerpts. Failure history (per risk factors): Phase 2 in advanced HCC (Child-Pugh B, post-Nexavar) missed its primary endpoint. No explicit discontinuation.

CF602

Stage not disclosed · Active Modality: orally bioavailable small molecule

Target A3AR (adenosine A3 receptor)

Status note Third pipeline molecule in the A3AR platform; no stage, trial, or indication stated in excerpts.

Per-asset detail extracted from the 20-F filed 2026-03-26. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	piclidenoson
Lead indication	Plaque Psoriasis
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06643260	Phase 3	Not yet recruiting	Sponsor	CANF	—	Plaque Psoriasis	—
NCT05201404	Phase 3	Recruiting	Sponsor	CANF	—	Hepatocellular Carcinoma; Cirrhosis	—
NCT07410455	Phase 2	Not yet recruiting	Sponsor	CANF	—	Lowe Syndrome	—
NCT06387342	Phase 2	Recruiting	Sponsor	CANF	—	Pancreatic Adenocarcinoma; Pancreatic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Can-Fite BioPharma on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CANF — Can-Fite Biopharma Ltd

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials